RxDoctor Payments Data

Shandra Wilson, MD

Urology · Greenwood Village, CONPI 1275557043

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (31.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Intuitive Surgical at 41.7% of the total. Reporting peaked in 2019 at $4,171 and has fallen 97.2% since, to $118 in 2024.

$8,607in general payments, 2019–2025

Across 95 payments — averaging $90.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • Shionogi Inc$2K
  • Coloplast$906
  • Novartis$378
  • Boston Scientific$342
  • Covidien LP$335
  • plus $1K from 21 others

What the payments were for

  • Consulting fees$2,33527%
  • Travel & lodging$2,58530%
  • Food & beverage$2,68731%
  • Education$1,00012%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,607 in reported general payments places this provider in the 75th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$310,282
Medicare patients
430
Services billed
2,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron121$118,170
GemtesaVibegron22$24,150
Testosterone21$7,214
Tamsulosin Hcl246$2,920
Methenamine Hippurate16$1,181
Oxybutynin Chloride38$861
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$846
Finasteride40$597
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$386
Solifenacin Succinate13$362
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim68$308
Ciprofloxacin Hcl42$261
Levofloxacin41$228
CefuroximeCefuroxime Axetil14$195
Alfuzosin Hcl ErAlfuzosin Hcl14$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$211$118,170121 claims
Sumitomo Pharma America, Inc.Gemtesa$38$24,15022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 225 urology providers in Colorado.

Other urology in Greenwood Village

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →